The world’s leading private supporter of novel research in lupus harnesses the power of innovation to drive scientific progress in this complex disease.
Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint
November 8, 2011
ACR Presentation by Lupus LA founder Daniel Wallace, MD
S.L.E. Lupus Foundation Board Member and Lupus LA founder Daniel Wallace, MD presented research at ACR demonstrating the effectiveness of a new sensitive composite measure of disease activity in lupus used successfully in two clinical trials.